Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This polyherbal formulation, developed by Composite Interceptive Med Science, is a combination of *Curcuma longa* (turmeric), *Zingiber officinale* (ginger), and *Ocimum sanctum* (tulsi/holy basil). It is primarily being evaluated for the management of frailty in the elderly population. The formulation leverages the synergistic effects of its botanical constituents: curcuminoids from turmeric provide potent anti-inflammatory and antioxidant properties by inhibiting pro-inflammatory cytokines and enzymes; gingerols and shogaols from ginger contribute additional anti-inflammatory and gastroprotective benefits; and tulsi acts as an adaptogen to enhance stress resilience and immune function. In clinical trial settings, the formulation is typically administered orally, often mixed with milk to improve palatability and potentially enhance the absorption of lipophilic compounds like curcumin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcuma longa + zingiber officinale + ocimum sanctum.